Greenwich LifeSciences (NASDAQ: GLSI)
Greenwich LifeSciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Greenwich LifeSciences Company Info
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
News & Analysis
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
Why Greenwich LifeSciences Stock Tanked Today
The drop came despite the clinical-stage biotech announcing good news over the weekend.
Why Greenwich LifeSciences Stock Is Rising Today
The company reported positive data for its cancer immunotherapy candidate GP2.
Why Greenwich LifeSciences Stock Skyrocketed Today
Investors cheered an important new hire.
This Was the Top-Performing IPO in 2020
A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.
Why Greenwich LifeSciences Stock Is Plunging Today
The company announced the pricing of a public offering of common stock.
Up 1,600% In 2 Days, Is It Too Late To Buy This Hot Biotech Stock?
Greenwich LifeSciences made investors rich overnight. Is there any growth left in this breast cancer treatment developer?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.